While the development of immunotherapies for cancer treatment offer significant promise across several cancers, still only a small subset of patients respond to immune based monotherapies. As such, attention has turned to the development of combination therapies. These use conventional cancer treatments such as chemotherapy to sensitise tumours to immunotherapy. Here, we summarise key research, highlighting the exciting potential of tumour associated glycans as therapeutic targets to sensitise tumours to immunotherapy. When cells undergo carcinogenesis they reprogram their glyco-code. Several cancer associated glycans have been identified, and therapies targeting them are under development. Proteins containing carbohydrate binding domains (lectins) are expressed by many immune cell subtypes, and upon glycan binding, transduce immune modulatory signals that regulate the tumour immune microenvironment.

中文翻译：

---

肿瘤相关聚糖：增强免疫治疗的途径吗？

尽管针对癌症治疗的免疫疗法的发展为多种癌症提供了广阔前景，但仍然只有一小部分患者对基于免疫的单一疗法产生反应。因此，注意力已经转向组合疗法的发展。这些使用常规的癌症治疗方法，例如化学疗法来使肿瘤对免疫治疗敏感。在这里，我们总结了关键研究，突出了肿瘤相关聚糖作为治疗靶点使肿瘤对免疫疗法敏感的令人兴奋的潜力。当细胞发生癌变时，它们会重新编程其糖代码。已经确定了几种与癌症相关的聚糖，针对它们的疗法正在开发中。含有碳水化合物结合结构域（凝集素）的蛋白质由许多免疫细胞亚型表达，并且在聚糖结合后，